GlassScriptPhysician profile
Pablo M Gonzalez
NPI 1124080759
$6,474.96
in general payments reported to CMS, 2019-2025
35 companies · $4,406 in 2025
The $4,406 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.97 · 2022: $400 · 2023: $717 · 2024: $930 · 2025: $4,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,586 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Travel and Lodging: $1,434 · Education: $32.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,585.87 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Travel and Lodging | $1,434.32 |
| Education | $32.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avyxa Pharma, LLC | $3,622.43 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $542.02 | 2023-2025 | Libtayo, Lynozyfic |
| Pfizer INC. | $360.58 | 2022-2025 | |
| Janssen Biotech, INC. | $316.08 | 2022-2025 | Darzalex, Tecvayli, Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $198.72 | 2022-2025 | Opdivo, Opdualag |
| US Oncology Corporate, INC. | $184.41 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $143.44 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $112.41 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Pharmacyclics LLC, An Abbvie Company | $79.09 | 2022-2023 | Imbruvica, Epkinly |
| Kite Pharma, INC. | $79.06 | 2022-2025 | Yescarta |
| Astrazeneca Pharmaceuticals LP | $71.37 | 2022-2024 | Tagrisso, Calquence, Lynparza |
| Astellas Pharma US INC | $70.32 | 2022-2025 | Xospata, Padcev |
| Seagen INC. | $70.28 | 2022 | |
| Emd Serono, INC. | $62.23 | 2025 | |
| Array Biopharma INC | $50.62 | 2024-2025 | Braftovi, Lorbrena, Mektovi |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $49.25 | 2022-2023 | Onivyde, Tazverik, Somatuline Depot |
| Gilead Sciences, INC. | $42.59 | 2021-2022 | |
| Puma Biotechnology, INC. | $34.65 | 2022-2023 | |
| Legend Biotech USA INC. | $34.43 | 2024-2025 | Carvykti |
| Jazz Pharmaceuticals INC. | $34.01 | 2021-2025 | |
| Genentech USA, INC. | $33.49 | 2023 | Lunsumio, Polivy, Phesgo |
| Glaxosmithkline, LLC. | $32.16 | 2024 | Zejula, Jemperli |
| Takeda Pharmaceuticals U.S.A., INC. | $31.94 | 2023 | Alunbrig |
| Bayer Healthcare Pharmaceuticals INC. | $26.67 | 2023 | |
| Karyopharm Therapeutics INC. | $24.57 | 2022 | |
| Taiho Oncology, INC. | $23.74 | 2025 | |
| Azurity Pharmaceuticals, INC. | $20.57 | 2025 | Vivimusta, Danziten |
| Lilly USA, LLC | $20.56 | 2023 | Verzenio, Jaypirca, Retevmo |
| Accord Healthcare, INC. | $18.91 | 2025 | |
| Tersera Therapeutics LLC | $18.29 | 2025 | Xermelo |
| Coherus Oncology, INC. | $17.95 | 2023 | |
| Celgene Corporation | $17.67 | 2024 | Pomalyst |
| Daiichi Sankyo INC. | $15.67 | 2022 | |
| Eisai INC. | $14.78 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pablo Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.